Ignite Creation Date:
2024-05-06 @ 10:38 AM
Last Modification Date:
2024-10-26 @ 12:33 PM
Study NCT ID:
NCT03315039
Status:
COMPLETED
Last Update Posted:
2022-03-10
First Post:
2017-10-16
Brief Title:
Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia AML
Sponsor:
Moleculin Biotech Inc
Organization:
Moleculin Biotech Inc
Study Overview
Official Title:
Phase 12 Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia AML That is Refractory to or Relapsed After Standard Induction Therapy
Status:
COMPLETED
Status Verified Date:
2022-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multi-center open-label dose escalation study that will determine the maximum tolerated dose MTD and recommended Phase 2 dose RP2D of liposomal annamycin as a single agent for the treatment of subjects with AML that is refractory to or relapsed after standard induction therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None